GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nyxoah SA (XBRU:NYXH) » Definitions » Short Percentage of Float

Nyxoah (XBRU:NYXH) Short Percentage of Float


View and export this data going back to 2020. Start your Free Trial

What is Nyxoah Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Nyxoah's Short Percentage of Float

For the Medical Instruments & Supplies subindustry, Nyxoah's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nyxoah's Short Percentage of Float Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nyxoah's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Nyxoah's Short Percentage of Float falls into.


Nyxoah (XBRU:NYXH) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nyxoah SA (XBRU:NYXH) » Definitions » Short Percentage of Float
Comparable Companies
XTAE:ORBI XTAE:FBRT XTAE:BSEN XTAE:TATT XTAE:ISI ISRG XPAR:EL BDX XSWX:ALC TSE:7741 WST OCSE:COLO B RMD TSE:4543 XSWX:STMN BAX XPAR:DIM HOLX TSE:7733 COO
Traded in Other Exchanges
NYXH:USA 5YI:Germany
Address
Rue Edouard Belin 12, Mont-Saint Guibert, BEL, 1435
Website
https://www.nyxoah.com
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.